Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy

Yuriy V. Shebzukhov, Ekaterina P. Koroleva, Svetlana V. Khlgatian, Maria A. Lagarkova, Andrey A. Meshcheryakov, Mikhail R. Lichinitser, Julia Karbach, Elke Jager, Dmitry V. Kuprash, Sergei A. Nedospasov

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Thymidylate synthase (TYMS), the critical enzyme for DNA synthesis and a target for chemotherapy, was recently characterized as an oncogene and a potential target for specific immunotherapy. Here we report TYMS-specific antibody response in a fraction of colon cancer patients. Humoral immune response to TYMS is induced by chemotherapy using TYMS inhibitors, such as 5-fluorouracil (5-FU), and may be associated with tumor burden. Therefore, TYMS may serve as a useful serological biomarker for monitoring the course of disease and treatment in cancer patients.

Original languageEnglish (US)
Pages (from-to)88-93
Number of pages6
JournalImmunology Letters
Volume100
Issue number1
DOIs
StatePublished - Aug 15 2005
Externally publishedYes

Keywords

  • 5-Fluorouracil (5-FU)
  • Antibodies
  • Serology
  • Thymidylate synthase (TYMS)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy'. Together they form a unique fingerprint.

Cite this